Amino Acid PET Imaging: Transforming the Management of Gliomas

Written in collaboration with:

Nancy Ann Oberheim Bush, MD, PhD – Associate Professor of Neurosurgery and Neurology at University of California San Francisco (UCSF)

Javier Villanueva-Meyer, MD – Associate Professor of Radiology and Neurosurgery: Vice Chair Department of Radiology at University of California San Francisco (UCSF)

HIGHLIGHTS

- Accurate neuroimaging is critical for glioma management See more →
- MRI has several limitations in characterization of gliomas that can lead to under- or over-treatment of patients due to uncertainty and inconclusive results
  - Incomplete detection of tumor extent can lead to under-treatment See more →
  - Inability to differentiate tumor progression from treatment-related changes (TRC) results in uncertainty and can lead to under- or over-treatment See more →
  - Detection of pseudoresponse during anti-angiogenic therapy can lead to under-treatment See more →
  - The emotional toll of inconclusive imaging results impacts patients, their caretakers, and physicians alike See more →
- PET imaging in glioma management has gained considerable interest due to the extensive utilities of amino acid radiotracers See more →
  - Not all amino acid PET radiotracers are the same See more →
- Amino acid PET radiotracers in clinical practice have already been recommended by society guidelines See more →
- ^{18}F-FET is the most studied and commonly used amino acid PET radiotracer with proven high diagnostic performance and accuracy in a broad range of clinical applications:
  - Differentiation of tumor progression or recurrence from TRC See more →
  - Monitoring treatment response See more →
  - Delineation of tumor extent for treatment planning See more →
  - Differential diagnosis, tumor grading, and prognostication at initial diagnosis See more →
- ^{18}F-FET PET imaging informs physicians to make confident clinical decisions and help resolve clinical dilemmas See more →

Initial content for this paper provided by Telix Pharmaceuticals. Drs. Oberheim-Bush and Villanueva-Meyer served as editors to this paper, including revising the content. Drs. Oberheim-Bush and Villanueva-Meyer received compensation for their contributions from Telix.

GLIOMAS AND NEUROIMAGING

Approximately 80,000 primary brain tumors are newly diagnosed each year in the United States. About 20,000 of those (~25%) are gliomas and about 12,000 (~15%) of those are glioblastoma, which is the highest grade (grade 4) and most aggressive form of glioma.[1] Only <5% of patients with glioblastoma survive 5 years following diagnosis.[8] Patients with glioblastoma who are treated with maximal safe tumor resection, radiochemotherapy, and adjuvant chemotherapy have a median overall survival of ~15 months.[3]

Accurate neuroimaging plays a critical role in the management of all gliomas.[3,6] Contrast-enhanced magnetic resonance imaging (MRI) is the primary imaging modality for patients with glioma along the disease journey, including initial diagnosis, presurgical planning, evaluation of residual tumor right after surgery, planning for radiotherapy , and monitoring during chemotherapy, as well as detection and definition of disease progression.[3] However, MRI can be unreliable as a surrogate for tumor size or growth as contrast-enhancement nonspecifically reflects vascular pathology and permeability of the contrast agent across a disrupted blood-tumor barrier.[3]

LIMITATIONS OF GLIOMA IMAGING WITH MRI

Incomplete detection of tumor extent

MRI can underestimate tumor burden in areas of the tumor that lack vascular pathology because it only detects sites of blood-brain barrier (BBB) disruption and vascular leakage.[5] Progression of glioma is almost inevitable and tumor cells can infiltrate beyond the contrast-enhancing component, which makes up the non-contrast-enhancing tumor.9 Non-contrast-enhancing tumor also has high malignancy potential and greater residual non-contrast-enhancing tumor is associated with poor prognosis.[9] Therefore, inaccurate delineation of the tumor volume can lead to under-treatment during surgical resection and radiotherapy, contributing to poor clinical prognoses and recurrent tumors.[5]

Contrast enhancement on MRI nonspecifically reflects vascular pathology, and thus, it may[3,5]:

- underestimate tumor burden due to its inability to detect non-contrast-enhancing tumor, leading to under-treatment
- falsely detect treatment-related changes as tumor progression, which results in uncertainty and may lead to over-treatment

INABILITY TO DIFFERENTIATE TUMOR PROGRESSION OR RECURRENCE FROM TREATMENT-RELATED CHANGES (TRC)

Treatments of glioma, such as radiotherapy, chemotherapy, corticosteroids, antiangiogenic and immunotherapy agents, also affect vascular permeability of tumors and MRI detects these changes potentially as progression or recurrence.[3] Therefore, the inability of MRI to differentiate between TRC and true tumor progression or recurrence may also result in under- or over-treatment.[4,5,7]

Common scenarios observed by MRI attributed to TRC, but mimicking tumor progression are[4,5,7]:

- Pseudoprogression (PsP), observed in ~30% of cases, is an acute response that manifests within 3 to 6 months after treatment due to tissue inflammation resulting in increased blood vessel permeability
- Radiation necrosis, observed in ~24% of cases, is a delayed effect of radiation therapy due to the damage to the vascular and glial cells leading to cell death

LIMITATIONS OF GLIOMA IMAGING WITH MRI

Incomplete detection of tumor extent

MRI can underestimate tumor burden in areas of the tumor that lack vascular pathology because it only detects sites of blood-brain barrier (BBB) disruption and vascular leakage.[5] Progression of glioma is almost inevitable and tumor cells can infiltrate beyond the contrast-enhancing component, which makes up the non-contrast-enhancing tumor.[9] Non-contrast-enhancing tumor also has high malignancy potential and greater residual non-contrast-enhancing tumor is associated with poor prognosis.[9] Therefore, inaccurate delineation of the tumor volume can lead to under-treatment during surgical resection and radiotherapy, contributing to poor clinical prognoses and recurrent tumors.[5]

DETECTION OF PSEUDORESPONSE

Pseudoresponse is the perceived reduction in the size of lesions by MRI during anti-angiogenic treatment due to restoration of the BBB and reduced vascular permeability rather than an actual impact on the tumor size.[4,10,11] This pseudoresponse adds ambiguity to MRI interpretation and may lead to under-treatment.[12]

THE EMOTIONAL TOLL OF INCONCLUSIVE IMAGING RESULTS

MRI signal changes may be related not only to treatment-related changes due to radiotherapy or chemoradiation with alkylating agents, but also to infection or neuroinflammation, ischemia, and demyelination.[13] All these changes can be difficult to distinguish from tumor recurrence and require repeat MRIs, resulting in uncertainty of clinical decisions that can last for several months.[13,14] This uncertainty may result in further distress and impacts everyone living with and managing glioma.[14,15] Importantly, it has a substantial emotional toll: patients and their loved ones experience extreme stress and worry as they wait for the results, while the physicians feel disappointed and stressed for not having clear answers or a plan of action.[15]

Amino acid PET, specifically ^{18}F-FET PET, is widely used to complement even advanced MRI methods. This underscores the value of amino acid PET beyond these supplementary MRI techniques.[4,7]

PET IMAGING IN GLIOMA MANAGEMENT

PET imaging can guide clinical decision making by providing molecular, functional, and metabolic information and complement the morphological data.[16,17] While ^{18}F-fluorodeoxyglucose (^{18}F-FDG) PET is extensively used in imaging of multiple tumor types, it has several limitations in imaging of brain tumors due to high glucose metabolism in normal brain tissue, leading to a high background signal and a decreased tumor-to-background ratio.[5,6,17] Additionally, ^{18}F-FDG PET is fraught with challenges similar to that of MRI in the differentiation of tumor recurrence from TRC due to the elevated glucose metabolism at sites of inflammation, such as those caused by radiation.[5] Amino acid PET radiotracers have been developed to bridge the gap in the management of gliomas and have primarily been used in Europe in diagnosis, biopsy, and resection as well as radiotherapy planning, treatment monitoring, and response assessment.[3-5,16,17]

AMINO ACID PET RADIOTRACERS

Amino acid PET radiotracers are transported into the tumor cells via amino acid transport systems, most commonly through the L amino acid transport (LAT1 and LAT2).[5,6] LAT1 has increased expression in gliomas, making it a valuable target for PET imaging as well as treatment.[5,6,17-19] LAT1 is also abundantly expressed both on the luminal and abluminal membrane side of the capillary endothelial cells that make up the BBB so it shuttles amino acid radiotracers across an intact BBB.[19] These radiotracers' ability to cross the BBB and their high tumor-to-brain uptake allow for improved accuracy in visualization of tumor extent with amino acid PET imaging.[5,6,17]

Not all amino acid radiotracers are the same.[4,5,7,18,20]

Three of the most commonly used amino acid radiotracers that are transported via LAT1 are ^{11}C-MET, ^{18}F-FDOPA, and ^{18}F-FET.[3,5,7] Another amino acid tracer that has more recently been studied in imaging of brain metastases is anti-1-amino-3-^{18}F-fuorocyclobutane-1-carboxylic acid (^{18}F-FACBC), also known as ^{18}F-fluciclovine, and it is primarily transported via alanine-cysteine-serine transporter (ASCT2).[5,20] Because ASCT2 is only located at the abluminal side of the BBB facing the brain, it cannot shuttle its substrates from the plasma across an intact BBB.21 In support of this, a recent study revealed that higher uptake of ^{18}F-fluciclovine was associated with tumors that have BBB disruption. Therefore, tumors with an intact BBB may be difficult to detect with ^{18}F-fluciclovine PET imaging.[20]

Among the amino acid PET radiotracers, ^{18}F-FET is the most studied and validated across various clinical applications for gliomas.[3-5,7,17] The longer half-life of ^{18}F (110 min) lends itself to logistical advantages over ^{11}C (half-life: 20 min). ^{18}F-FET has become the most widely used while ^{11}C-MET requires an on-site cyclotron and immediate imaging of ^{11}C.[4,7,18] Furthermore, ^{18}F-DOPA use has been limited due to its high uptake in the striatum leading to a high background and a poor signal-to-noise ratio.[4]

^{18}F-FET is the most validated amino acid PET radiotracer in a broad range of clinical applications.[3,4,7,17]


- Tumors with an intact BBB may be difficult to detect with ^{18}F-fluciclovine PET.[20]
- ^{11}C-MET has feasibility challenges with a short half-life and 18F-DOPA is limited with a high background in the striatum.[4,7,18]

AMINO ACID PET IMAGING IN CLINICAL PRACTICE

Utilization of PET imaging with amino acid radiotracers has been widely recognized and recommended by professional medical organizations.[3,16,17] In 2019, joint EANM/EANO/RANO practice guidelines and SNMMI procedure standards recommended use of PET imaging with amino acid radiotracers across several clinical applications in glioma management (**Figure 1**).[3]

Figure 1

Key milestones in the clinical journey of patients with glioma and various applications of amino acid PET imaging recommended by the joint EANM/EANO/RANO practice guidelines and SNMMI procedure standards.[3]



These recommendations provided extensive information on amino acid PET imaging from radiopharmaceutical preparation to image acquisition and interpretation, including threshold values for PET parameters in various clinical applications such as: biological tumor volume (BTV), static (mean and maximum tumor to background ratios, TBR) and dynamic (time activity curves and time to peak, TTP) PET parameters.[3]

Recently in 2024, PET RANO 1.0 established a set of criteria for a standardized framework in the response assessment of amino acid PET imaging in clinical trials of gliomas.[17] These criteria provide a framework to facilitate implementation of amino acid PET imaging into clinical research and, ultimately, into clinical practice.[17]

EANM/EANO/RANO and SNMMI recommendations for amino acid PET imaging include clinical applications at initial diagnosis, such as definition of high- vs low-grade gliomas, prognostication, definition of the biopsy site, delineation of tumor extent for surgery or radiotherapy, monitoring of treatment response, and diagnosis of tumor progression.[3,17] Below is a summary of ^{18}F-FET PET data in these clinical applications.

Amino acid PET imaging, including ^{18}F-FET PET, is recommended by the EANM/EANO/RANO/SNMMI and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in various clinical applications for glioma.[3,7,54]

In April 2026 the NCCN Guidelines® for CNS Cancers included the amino acid radiotracers - ^{18}F-FET, ^{11}C MET, FDOPA - as evidence NCCN Category 2A for primary and secondary brain tumor PET imaging.[54] According to the joint RANO, EANO, and SNMMI guidelines, amino acid PET may be utilized for the delineating tumor extent, guiding stereotactic biopsy, improving radiotherapy planning, and distinguishing tumor progression from treatment-related effects. When combined with MRI, reported sensitivities and specificities for these applications often approach or exceed 90% across multiple studies.

^{18}F-FET PET IMAGING IN MANAGEMENT OF BRAIN TUMORS

^{18}F-FET PET imaging in differentiation of tumor progression or recurrence from TRC

Inconclusive MRI results are a common occurrence for many patients with brain tumors.[5] Thus, perhaps the most pressing unmet need that ^{18}F-FET PET imaging addresses in the management of brain tumors is the differentiation of tumor progression or recurrence from TRC.[4] As described earlier, changes in MRI signal suggesting tumor progression or recurrence are frequently observed after radiotherapy and/or chemotherapy or immunotherapy, but whether these changes are in fact related to treatment (ie, TRC) can be uncertain in a sizable patient population.[4,5,7]

Multiple studies have demonstrated high accuracy of more than 95% with 18F-FET PET imaging for differentiation of TRC from tumor progression or recurrence.[22-26] Similar results of more than 90% accuracy have been reported with ^{18}F-FET PET imaging for brain metastases to differentiate TRC from progression or recurrence suspected with MRI.[27-29]

A recent systematic review and meta-analysis of 1206 patients from 21 studies in high-grade gliomas (HGG) and 5 studies in brain metastasis evaluated 18F-FET PET imaging for differentiating TRC from tumor progression or recurrence suspected with MRI.[30] In 6 studies using static TBRmax (cut-off value: 1.9-2.3), the authors reported a pooled sensitivity and specificity of 91% and 84%, respectively. Additionally, a diagnostic accuracy of up to more than 90% was reported using combined static and dynamic ^{18}F-FET PET parameters for the characterization of both recurrent gliomas (4 studies) and brain metastases (all 5 studies).[30]

^{18}F-FET PET imaging complements MRI to address its shortcomings.[3,4,30]

^{18}F-FET PET imaging in monitoring treatment response

^{18}F-FET PET imaging has also proven to be successful for the assessment of treatment response to plan for an optimal treatment strategy and help avoid over-treatment and unnecessary side effects.[7,31] ^{18}F-FET PET imaging after surgery and radiochemotherapy have provided valuable prognostic information.[4,7,31] ^{18}F-FET PET detected residual tumor more frequently than MRI and its results were not influenced if performed >72 hours post-resection.[31,32] Furthermore, higher ^{18}F-FET uptake and higher residual tumor volume were associated with tumor recurrence and poor overall survival, respectively.[31,33,34]

^{18}F-FET PET imaging has also been evaluated in the assessment of treatment response in glioma. Early reduction in ^{18}F-FET uptake was shown to be a positive prognostic factor following postoperative chemoradiation.[4,7] Early responders identified by ^{18}F-FET PET imaging within 7 to 10 days after chemoradiation were defined as those with more than a 10% reduction in ^{18}F-FET uptake and they were correlated with a significantly longer progression-free survival and overall survival compared with nonresponders.[35,36] Recent evidence also supported the use of ^{18}F-FET PET imaging in patients with brain metastases for monitoring of response to emerging treatments like targeted therapy and immunotherapy.[37]

^{18}F-FET PET imaging provides valuable prognostic information and guidance for an optimal treatment strategy through monitoring of treatment response.[4,7,31]

As described earlier, another limitation of MRI is pseudoresponse to anti-angiogenic therapies because contrast enhancement can be reduced due to restoration of the BBB with these therapies.[4,10,11] ^{18}F-FET PET imaging was also shown to differentiate response to anti-angiogenic therapies earlier than MRI alone.[38-41] In two prospective studies, a response detected by ^{18}F-FET PET predicted a significantly longer overall survival benefit and provided critical information for clinical management while MRI did not.[39,40]

^{18}F-FET PET imaging in delineation of tumor extent for treatment planning

^{18}F-FET PET imaging can also address the MRI limitation of underestimating the tumor burden due to its reliance on BBB disruption for tumor detection.[4,6,7] As discussed earlier, 18F-FET precisely detects increased metabolic activity of the tumor, which is manifested by upregulation of LAT1, and its uptake is independent of BBB disruption.[5,6] As a result, ^{18}F-FET can detect tumor tissue beyond the contrast enhancement of MRI, ie, non-CET component of the tumor.9 Therefore, ^{18}F-FET PET imaging helps minimize false negative results that mislead biopsies and planning for surgery or radiotherapy, all of which can result in under-treatment and contribute to recurrent tumors and poor clinical prognoses.[4,42]

^{18}F-FET PET imaging is proven to improve the accurate delineation of tumor extent to avoid under-treatment by informing biopsy and treatment planning.[4,6,7,42]

Utility of ^{18}F-FET PET to improve detection of the tumor extent in gliomas, including non-contrastenhancing gliomas, has been demonstrated in several biopsy-controlled studies.[42-47] Studies that compared ^{18}F-FET PET with conventional or advanced MRI, such as MR spectroscopic imaging, revealed that combination of MRI with ^{18}F-FET PET improved delineation of tumor extent.[43,44,47-49] These results support combined use of ^{18}F-FET PET and MRI to obtain a more accurate delineation of tumor extent for informing individualized biopsy and treatment planning.[43,44,48,49]

^{18}F-FET PET imaging at initial diagnosis

At initial diagnosis, ^{18}F-FET PET has been evaluated for differential diagnosis, tumor grading, and prognostication.[3] Tumor grading with ^{18}F-FET PET is limited to data based on 2007 WHO classification which may no longer be applicable after the significant changes introduced to glioma classification in 2016 and more recently in 2021 based on advances in molecular characterization.[7,50] Also, while there is compelling evidence for prognostically relevant information with ^{18}F-FET PET, such as biological tumor volume and low uptake indicating better prognosis, further research is needed to establish the associated prognostic factors.[4,7]

Nonetheless, ample data support the use of ^{18}F-FET PET in differential diagnosis of neoplastic and nonneoplastic lesions if a lesion is detected by MRI. Evidence suggests that ^{18}F-FET uptake is higher in neoplastic lesions (ie, primary and metastatic brain tumors) than non-neoplastic lesions, such as inflammatory processes, hemorrhage, infarction, and infection.[4,7] In a meta-analysis of 13 studies that included 462 patients confirmed with histopathology comparison, ^{18}F-FET PET had a pooled sensitivity of 82% and specificity of 76% to distinguish primary brain tumors from non-neoplastic lesions.[7,51]

While histological evaluation has been the gold standard to provide an accurate characterization of brain lesions, ^{18}F-FET PET imaging can help with differential diagnosis by evaluation of equivocal brain lesions.[7]

IMPACT OF ^{18}F-FET PET IMAGING ON CLINICAL MANAGEMENT


In patients with equivocal findings on MRI, ^{18}F-FET PET/MRI has proven to be a valuable add-on diagnostic tool in brain tumors.[52] Data from studies in routine clinical setup started to unveil the impact of ^{18}F-FET PET/MRI on clinical management in addition to diagnostic performance.[52,53] Such real-world data can address the limited evidence for a direct comparison of ^{18}F-FET PET and MRI due to the challenges associated with randomized, controlled trials.[52]

A retrospective study evaluated the diagnostic performance of ^{18}F-FET PET/MRI and changes in clinical management of patients who had equivocal standard imaging results or clinical course.[52] This study included 189 patients who were newly diagnosed with untreated lesions suspected of malignancy, or who had suspected progression during adjuvant treatment. The authors used histologic confirmation or clinical and standard imaging follow up as the reference standard. At new diagnosis, 18F-FET PET/MRI identified malignancy with an accuracy of 85% and changed the clinical management in 33% of the previously equivocal patients. ^{18}F-FET PET/MRI also identified true progression with an accuracy of 93% and changed the clinical management in 53% of the cases of tumor progression (Figure 2).[52]

Most recently, a prospective study of 80 patients with Grade 3-4 gliomas or brain metastases who had ambiguous MRI results evaluated the diagnostic performance of ^{18}F-FET PET/MRI and its impact on management decisions.[53] Patients were monitored for at least 6 months to confirm the diagnosis using pathology, imaging, and clinical progress. ^{18}F-FET PET/MRI had a sensitivity of 86%, specificity of 87%, and accuracy of 86% in cases for which MRI had an accuracy of 66%. Detection of tumor progression led to clinical management changes in 88% of cases while clinical management was maintained in 87% of cases when TRC was detected.[53]

Figure 2

Frequency of clinical management changes based on ^{18}F-FET PET/MRI outcome at initial tumor diagnosis (dark blue) and at detection of brain tumor progression (light blue).[52] Active treatment to monitoring was defined as waiving of invasive diagnostics for tumor characterization or waiving of surgery/adjuvant therapy during disease course. Monitoring to active treatment was defined as subsequent invasive diagnostics, or treatment start. Therapy stratification was defined as beginning of/waiving additional adjuvant treatment, or waiving planned change and continuing present treatment, or shifting from adjuvant therapy to surgery or vice versa, or changing of adjuvant treatment. Treatment adaptation was defined as change of location/extent of biopsy/resection, or adjustment of irradiation volume/chemotherapy dose.[52]



Adapted from Brendle C, et al. J Nucl Med. 2022;63(4):522-527.

These real-world results support the use of ^{18}F-FET PET/MRI to improve confidence in clinical decisions by clarifying equivocal standard imaging results, avoiding unnecessary invasive procedures and distinguishing TRC from tumor recurrence or progression.[52,53]

Recent findings demonstrating the impact on management decisions add to a growing body of evidence that ^{18}F-FET PET complements and improves MRI results.[52,53]

REFERENCES

1. Mesfin FB, Al-Dhahir MA. Gliomas. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Updated May 20, 2023. Accessed December 1, 2023. https://www.ncbi.nlm.nih.gov/books/NBK441874/
2. Grochans S, Cybulska AM, Simińska D, et al. Epidemiology of glioblastoma multiforme–literature review. Cancers (Basel). 2022;14(10):2412 doi:10.3390/cancers14102412
3. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-557. doi:10.1007/s00259-018-4207-9
4. Stegmayr C, Stoffels G, Filß C, et al. Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F] FET) in neurooncology. Nucl Med Biol. 2021;92:78-84. doi:10.1016/j. nucmedbio.2020.02.006
5. Muthukumar S, Darden J, Crowley J, Witcher M, Kiser J. A comparison of PET tracers in recurrent high-grade gliomas: A systematic review. Int J Mol Sci. 2022;24(1):408. doi:10.3390/ijms24010408
6. Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021;23(6):881-893. doi:10.1093/neuonc/noab013
7. Langen KJ, Stoffels G, Filss C, et al. Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET). Methods. 2017;130:124-134. doi:10.1016/j.ymeth.2017.05.019
8. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, ed. Glioblastoma. Brisbane (AU): Codon Publications; 2017.
9. Lasocki A, Gaillard F. Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am J Neuroradiol. 2019;40(5):758-765. doi:10.3174/ajnr.A6025
10. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729. doi:10.1200/JCO.2007.12.2440
11. Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20(1):110-119. doi:10.1016/S1470-2045(18)30675-2
12. Autry A, Phillips JJ, Maleschlijski S, et al. Characterization of metabolic, diffusion, and perfusion properties in GBM: contrast-enhancing versus non-enhancing tumor. Transl Oncol. 2017;10(6):895-903. doi:10.1016/j.tranon.2017.08.009
13. Rosen J, Ceccon G, Bauer EK, et al. Cost effectiveness of 18F-FET PET for early treatment response assessment in glioma patients after adjuvant temozolomide chemotherapy. J Nucl Med. 2022;63(11):1677-1682. doi:10.2967/jnumed.122.263790
14. Abdalla G, Hammam A, Anjari M, D'Arco DF, Bisdas DS. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook. BJR Open. 2020;2(1):20200009. doi:10.1259/bjro.20200009
15. Young JS, Al-Adli N, Sibih YE, et al. Recognizing the psychological impact of a glioma diagnosis on mental and behavioral health: a systematic review of what neurosurgeons need to know. J Neurosurg. 2022; 139(1):11-19. doi:10.3171/2022.9.JNS221139
16. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199-1208. doi:10.1093/neuonc/now058
17. Albert NL, Galldiks N, Ellingson BM, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25(1):e29-e41. doi:10.1016/S1470-2045(23)00525-9.
18. Götz I, Grosu AL. [(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients - a review. Front Oncol. 2013;3:104. doi:10.3389/fonc.2013.00104
19. Li L, Di X, Zhang S, et al. Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. Colloids Surf B Biointerfaces. 2016;141:260-267. doi:10.1016/j.colsurfb.2016.01.041
20. Scarpelli ML, Healey DR, Mehta S, Quarles CC. Imaging glioblastoma with 18F-Fluciclovine amino acid positron emission tomography. Front Oncol. 2022;12:829050. doi:10.3389/fonc.2022.829050
21. Zaragoza R. Transport of amino acids across the bloodbrain barrier. Front Physiol. 2020;11:973. doi:10.3389/ fphys.2020.00973
22. Bashir A, Mathilde Jacobsen S, Mølby Henriksen O, et al. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Neuro Oncol. 2019;21(12):1595-1606. doi:10.1093/neuonc/noz166

23. Werner JM, Stoffels G, Lichtenstein T, et al. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI. Eur J Nucl Med Mol Imaging. 2019;46(9):1889-1901. doi:10.1007/s00259-019-04384-7
24. Galldiks N, Dunkl V, Stoffels G, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42(5):685-695. doi:10.1007/s00259-014-2959-4
25. Galldiks N, Stoffels G, Filss C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015;17(9):1293-1300. doi:10.1093/neuonc/nov088
26. Rachinger W, Goetz C, Pöpperl G, et al. Positron emission tomography with O-(2-[18F] fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005;57(3):505-511. doi:10.1227/01.neu.0000171642.49553.b0
27. Galldiks N, Stoffels G, Filss CP, et al. Role of O-(2-(18) F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med. 2012;53(9):1367-1374. doi:10.2967/ jnumed.112.103325
28. Lohmann P, Kocher M, Ceccon G, et al. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. Neuroimage Clin. 2018;20:537-542. doi:10.1016/j.nicl.2018.08.024
29. Akhoundova D, Hiltbrunner S, Mader C, et al. 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer. Clin Nucl Med. 2020;45(2):113-117. doi:10.1097/RLU.0000000000002890
30. Singnurkar A, Poon R, Detsky J. 18F-FET-PET imaging in high-grade gliomas and brain metastases: a systematic review and meta-analysis. J Neurooncol. 2023;161(1):1-12. doi:10.1007/s11060-022-04201-6
31. Langen KJ, Heinzel A, Lohmann P, Mottaghy FM, Galldiks N. Advantages and limitations of amino acid PET for tracking therapy response in glioma patients. Expert Rev Neurother. 2020;20(2):137-146. doi:10.1080/14737175.2020.1704256
32. Buchmann N, Kläsner B, Gempt J, et al. 18F-Fluoroethyll- Thyrosine positron emission tomography to delineate tumor residuals after glioblastoma resection: A comparison with standard postoperative magnetic resonance imaging. World Neurosurg. 2016;89:420-426. doi:10.1016/j.wneu.2016.02.032
33. Buchmann N, Gempt J, Ryang YM, et al. Can early postoperative O-(2-18F-Fluoroethyl)-l-Tyrosine positron emission tomography after resection of glioblastoma predict the location of later tumor recurrence? World Neurosurg. 2019;121:e467-e474. doi:10.1016/j.wneu.2018.09.139
34. Müther M, Koch R, Weckesser M, Sporns P, Schwindt W, Stummer W. 5-Aminolevulinic acid fluorescenceguided resection of 18F-FET-PET positive tumor beyond gadolinium enhancing tumor improves survival in glioblastoma. Neurosurgery. 2019;85(6):E1020-E1029. doi:10.1093/neuros/nyz199
35. Piroth MD, Pinkawa M, Holy R, et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;80(1):176-184. doi:10.1016/j.ijrobp.2010.01.055
36. Galldiks N, Langen KJ, Holy R, et al. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI [published correction appears in J Nucl Med. 2013 Oct;54(10):1846]. J Nucl Med. 2012;53(7):1048-1057. doi:10.2967/jnumed.111.098590
37. Galldiks N, Lohmann P, Fink GR, Langen KJ. Amino acid PET in neurooncology. J Nucl Med. 2023;64(5):693-700. doi:10.2967/jnumed.122.264859
38. Hutterer M, Nowosielski M, Putzer D, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent highgrade glioma. J Nucl Med. 2011;52(6):856-864. doi:10.2967/ jnumed.110.086645
39. Galldiks N, Rapp M, Stoffels G, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2013;40(1):22-33. doi:10.1007/s00259-012-2251-4
40. Galldiks N, Dunkl V, Ceccon G, et al. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. Eur J Nucl Med Mol Imaging. 2018;45(13):2377-2386. doi:10.1007/s00259-018-4082-4
41. Galldiks N, Werner JM, Tscherpel C, Fink GR, Langen KJ. Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI. Neurooncol Adv. 2019;1(1):vdz038. doi:10.1093/noajnl/vdz038

42. Lopez WO, Cordeiro JG, Albicker U, et al. Correlation of 18F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther. 2015;8:3803-3815. doi:10.2147/OTT.S87126 Amino Acid PET Imaging: Transforming the Management of Gliomas
43. Song S, Cheng Y, Ma J, et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging. 2020;47(6):1458-1467. doi:10.1007/s00259-019-04656-2
44. Lohmann P, Stavrinou P, Lipke K, et al. FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2019;46(3):591-602. doi:10.1007/s00259-018-4188-8
45. Rapp M, Heinzel A, Galldiks N, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54(2):229-235. doi:10.2967/jnumed.112.109603
46. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36(7):779-787. doi:10.1016/j.nucmedbio.2009.05.005
47. Pauleit D, Floeth F, Hamacher K, et al. O-(2-[18F] fluoroethyl)- L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128(Pt 3):678-687. doi:10.1093/brain/awh399
48. Verburg N, Koopman T, Yaqub MM, et al. Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. Neuro Oncol. 2020;22(3):412-422. doi:10.1093/neuonc/noz180
49. Mauler J, Lohmann P, Maudsley AA, et al. Diagnostic accuracy of MR spectroscopic imaging and 18F-FET PET for identifying glioma: a biopsy-controlled hybrid PET/MRI study. J Nucl Med. 2023;00:1-6. doi:10.2967/jnumed.123.265868
50. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106
51. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med. 2012;53(2):207-214. doi:10.2967/jnumed.111.096859
52. Brendle C, Maier C, Bender B, et al. Impact of 18F-FET PET/ MRI on clinical management of brain tumor patients. J Nucl Med. 2022;63(4):522-527. doi:10.2967/jnumed.121.262051
53. Smith NJ, Deaton TK, Territo W, et al. Hybrid 18F-Fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases. J Nucl Med. 2023;64(7):1087-1092. doi:10.2967/jnumed.122.265149
54. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers V.3.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 14, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Telix

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates.
© 2026 Telix Pharmaceuticals (US) Inc. All rights reserved. US-2300059 09/2026